TBPH earnings analysis
What we found in TBPH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 revenue was $20.731 million, up 11% year over year and approximately 15% sequentially from $18 million, with a 100.0% gross margin. However, GAAP results deteriorated to a $5.898 million net loss and negative $0.11 diluted EPS from prior-year net income of $54.835 million, which benefited from a $75.137 million gain. The key forward catalysts are the expected second-half 2026 Zymeworks closing and restructuring benefits of approximately $70 million in full-run-rate savings and $60-$70 million of annualized cash flow, while merger execution, YUPELRI pricing and supply concentration, and the failed ampreloxetine program remain significant risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- YUPELRI Revenue Increased 11%
- YUPELRI collaboration revenue increased 11% year over year to $20.731 million. The filing also describes YUPELRI demand growth and continued profitability at the brand level since the third quarter of 2020.
- Revenue Rebounded Sequentially
- The company reported a gross margin of 100.0% for the quarter, consistent with its collaboration-revenue model. Revenue was $20.731 million versus $18 million in the immediately preceding quarter, an increase of approximately 15%.
- Restructuring Savings Provide Cash Support
- Restructuring actions are expected to deliver approximately $70 million of full-run-rate cost savings and $60-$70 million of annualized cash flow beginning in the second half of 2026.
- $387.7 Million Liquidity Position
- Liquidity appears substantial: cash, cash equivalents and marketable securities totaled approximately $387.7 million as of June 30, 2026, and management believes funding is sufficient for anticipated operating needs for at least the next twelve months.
- YUPELRI Generic Litigation Settled
- All YUPELRI generic litigation with the identified applicants had been settled as of March 31, 2026, with licensed generic launch generally deferred until April 23, 2039, subject to exceptions and other provisions.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- GAAP Results Declined Sharply
- The company reported a GAAP net loss of $5.898 million, or diluted EPS of negative $0.11, for the quarter, compared with $54.835 million of net income, or $1.08 EPS, in the prior-year quarter; the prior-year result included a $75.137 million gain.
- Merger Closing Remains Conditional
- Completion of the pending Zymeworks merger requires, among other conditions, approval by holders of at least two-thirds of the ordinary shares represented and voting at the meeting, as well as expiration or termination of the Hart-Scott-Rodino waiting period.
- $32.5 Million Termination Fee
- Under specified termination circumstances, the merger agreement requires a cash termination fee of $32.5 million, which could reduce cash available for general corporate purposes.
- YUPELRI Single-Source Supply Risk
- YUPELRI has a single supplier for API, a single supplier for drug product, and is warehoused in a single facility, creating concentrated supply-chain exposure despite current demand growth.
- Ampreloxetine Program Failure
- The company wound down the ampreloxetine program after the Phase 3 CYPRESS study failed to meet its primary endpoint in March 2026. Any future CVR value is highly speculative, and shareholders are entitled to 80% of net proceeds only if a qualifying monetization occurs during the next ten years.
- Reporting Requirements Increase in 2027
- The company determined it will no longer qualify as a smaller reporting company beginning in 2027, although it may use reduced reporting requirements through its 2026 Form 10-K; the transition could increase reporting demands and costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.11
- Gross margin
- 100.0%
- Segment
- YUPELRI collaboration revenue: $20.731 million, up 11% year over year; no separately reported operating segments disclosed.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects the Zymeworks acquisition to close in the second half of 2026, subject to shareholder approval and customary closing conditions. The restructuring is expected to generate approximately $70 million of full-run-rate cost savings and $60-$70 million of annualized cash flow beginning in the second half of 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Theravance Biopharma reported strong financial results for Q1 2026, with revenue increasing to $17.7 million, primarily driven by YUPELRI sales, though the company posted a net loss of $4.9 million. The company also…
- 10-K · March 23, 2026
- Theravance Biopharma, Inc. reported a net income of $105.9 million for the year ended December 31, 2025, signaling a significant recovery after losses in the previous two years. Total revenues rose to $107.5 million,…
- 10-Q · November 12, 2025
- Theravance Biopharma, Inc. reported steady revenue growth in Q3 2025 with total revenue increasing to $20 million, a 19% increase year-over-year. The company recorded earnings per share (EPS) of $0.07, a turnaround from…
- 10-Q · August 13, 2025
- Theravance Biopharma achieved a notable turnaround in Q2 2025, posting a revenue of $26 million and a diluted EPS of 1.08, compared to a loss of -0.34 per share in Q2 2024. The significant rise in revenue, driven…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TBPH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever